Share on

Global Viral Inactivation Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Method, Product, Application, End-Users & Region - Industry Forecasts (2022 to 2027)

Published: January, 2022
ID: 3098
Pages: 175
Formats: report pdf report excel report power bi report ppt

Viral Inactivation Market Size (2022 to 2027)

The global viral inactivation market size is forecasted to be worth USD 910.89 million by 2027, from worth USD 501.01 million in 2022, growing at a CAGR of 12.7% between 2022 to 2027.

Viral Inactivation is the procedure in which viral cells are killed or made inactive. This procedure is primarily performed to enhance safety and prevent viruses in the sample from contaminating the desired product. The virus may be present in the final product but an inactive form. The range of inactivation techniques is performed chiefly in food and blood plasma industries to protect them from viral activity. Viral Inactivation is achieved by treating with dry heat, decreasing the pH all the way till 4, solvent/detergent usage, irradiation by UV rays, and pasteurization others.

Viral inactivation using solvents and detergents is the most used in the blood plasma industry; however, it is effective only for viruses enveloped by lipid molecules. The detergents/solvents interact with the lipid molecules in which viruses are present, thus rendering them ineffective as they cannot survive without lipid molecules. Pasteurization is effective when the proteins which are to be protected are more thermally resistant than the viruses. Similarly, lowering pH is effective when the molecules which are to be protected are more resistant than viruses. UV radiations cause damage to the DNA of living cells by creating nucleic acid dimers, thus affecting the life cycle and reproduction processes.


The growth of the global viral inactivation market is driven by factors like the focus of research and development industries in life sciences and swift growth in pharmaceuticals and biotechnology industries, the rise of chronic diseases, rising support of the government in biotechnology and pharmaceuticals sectors, and launch of new drugs among others.

The main drivers of this market are increased investment in the life sciences industry, increased drug releases and approvals, and government support for the pharmaceutical and biopharmaceutical sectors in terms of funding. A rise in the global prevalence of chronic diseases such as cancer, autoimmune disorders, and other diseases, as well as an increase in healthcare spending, including an improving research and development investment climate, an increased risk of cell culture pollution, advances in nanofiltration technology, are driving the viral inactivation market. FDA approval leads to the commercialization of new medicines helps market expansion.

Increased outsourcing of pharmaceutical products and growth in developing markets would open up new opportunities for the viral clearance market. The medical industry's technological evolution is driving up demand for viral inactivation methods and the development of new and improved treatments to combat the increase in many diseases. Rising drug advances are also fueling the viral inactivation market's growth.


However, the global viral inactivation market is restrained by a smaller number of skilled workers and the incidence of strong consolidation. High costs associated with the manufacture of biosimilar products and high levels of competition are expected to restrict demand development in the forecast period. The shortage of qualified workers would pose a challenge to the viral inactivation market's growth. Some problems with the virus inactivation process, such as virus aggregate formulation, protein crosslinking, and protein denaturation and degradation, are limiting its market development even further.

Impact of COVID-19 on the global viral inactivation market:

The COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to the strict implementation of lockdown, nearly all industries got shut down and adversely impacted. The Viral Inactivation Market was positively impacted during the pandemic. Since Viral Inactivation is used to kill or inactive viral cells, the viral inactivation technique was done on the laboratory workers handling materials containing SARS-CoV-2 to improve the immunity, which accelerated the global viral inactivation market growth during the pandemic.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Analysed

By Method, Product, Application, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

Companies Analysed

Clean Cells, Charles River Laboratories International Inc, Danaher Corporation, Merck KGaA, Parker Hannifin, Red Source Technologies, Sartorius AG, SGS S.A, Texcell Inc, Viral Inactivated Plasma Systems SA, and Wuxi Pharma Tech Inc


This research report on the global viral inactivation market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2027.

Viral Inactivation Market - By Method:

  • Solvent/Detergent Method            
  • Pasteurization       
  • UV Radiation          
  • Microwave Heating             
  • High-Energy Light 

Based on the method, the largest market share is held by the solvent/detergent method since it requires less investment, easy to use, and a high degree of inactivation of viruses.

Viral Inactivation Market - By Product:                        

  • Kits and Reagents
  • Services    
  • Accessories               
  • Viral Inactivation Systems 

Due to their widespread use by pharmaceutical and biopharmaceutical firms, kits and reagents accounted for the largest market share based on the product.

Viral Inactivation Market - By Application:            

  • Vaccines and Therapeutics               
  • Stem Cell Products              
  • Cell Culture             
  • Gene Therapy       
  • Blood & Blood Products     

Based on application, Vaccines and therapeutics have the largest share in this segment due to increased government funding to promote the use of biologics to cure diseases and advances in biologics development.

Viral Inactivation Market - By End User:                    

  • Pharmaceutical and Biotechnology Companies       
  • Contract Research Organizations   
  • Academic Research Institutes    

Based on End-User, the demand for viral inactivation was dominated by pharmaceutical and biotechnology industries. This is primarily due to the expanded use of these goods for drug production and processing, fuelling the segment's expansion.     

Viral Inactivation Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the North American viral inactivation market is predicted to account for the largest share in the global market during the forecast period. The North America Viral Inactivation Market was valued at USD 152.42 million in 2020, and by 2025, the market was estimated to be growing at a CAGR of 13.1%, to reach USD 282.06 million. The swift growth in pharmaceuticals and biotechnology industries is driving the North American Viral Inactivation Market. In terms of sales, the United States has the highest market share in North America. This is mostly due to improved hospital systems, sophisticated equipment and technology, and rising healthcare costs. The rising incidence of chronic diseases and the growing focus of research and development in life sciences boost the US Viral Inactivation Market. For instance, the American Cancer Society 2019 had reported 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States only. Moreover, the government's rising support to develop the biotechnology and pharmaceutical sectors is fueling the market growth. Canada is increasing predominantly during the forecast period owing to the rise in pharmaceutical production. 

The size of the Europe Viral Inactivation Market is valued at USD 120.66 million in 2020. By 2025, the market is estimated to reach USD 213.60 million to grow at a CAGR of 12.1% during the forecast period. The European Viral Inactivation Market is driven by the increasing prevalence of chronic diseases and rapid growth in the pharmaceutical and biotechnology industries. Furthermore, the demand is boosted by a surge in new drug releases and increased research and development sectors in the life sciences. The rising incidence of chronic diseases and high growth in the pharmaceuticals and biotechnology industries drive the European Viral Inactivation Market. Moreover, the rise in new drug launches and increased research and development industries in life sciences boost the market. The presence of several market players in Europe is boosting the European Viral Inactivation Market. The UK and Germany are the major contributors to the European Viral Inactivation Market.


Some of the major players in the global viral inactivation market profiled in the report are Clean Cells, Charles River Laboratories International Inc, Danaher Corporation, Merck KGaA, Parker Hannifin, Red Source Technologies, Sartorius AG, SGS S.A, Texcell Inc, Viral Inactivated Plasma Systems SA, and Wuxi Pharma Tech Inc.


  • Rad Source Technologies introduced aspergillus, mold, mildew, and pathogen remediation technology in August 2019. This new technology is supported by the government and is popular in Canada and the Netherlands.
  • In September 2019, Merck KGaA announced the purchase of Pfizer Inc. and the introduction of BAVENCIO, a new medication that aims to cure a variety of illnesses, including cancers such as renal cell carcinoma, metastatic cancer and several others.
  • Clean Cells has acquired NAOBiOS, a company that develops viral vaccines and is used to cure various diseases, in 2019.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample